Johnson Matthey Receives Two Pharmaceutical and Biotech CMO Leaderships Awards in 2015
Johnson Matthey has been recognised in the 2015 CMO Leadership Awards for the Reliability and Regulatory Track record of its Pharma Services to the Biotech Industry.
The CMO Leadership Awards are presented by Life Science Leader Magazine and based upon extensive industry research conducted by Nice Insight, surveying thousands of industry executives from multiple industry segments across the globe.
The awards are presented to companies achieving top ranking against various criteria and for specific industry segments. Johnson Matthey was awarded in the two following categories:
• Reliability for Emerging Biotech Companies
• Regulatory Track Record for Biotech Companies
Commenting on the awards, Bernhard Paul, General Manager of Johnson Matthey Pharma Services said: “we are honoured to be recognised with the CMO Leadership Awards for Reliability and Regulatory track record. This is a testament to our culture of continuous improvement, customer focus, and our commitment to quality. Our team at Johnson Matthey Pharmaceutical Materials and Services focuses on creating value for our customers and providing them with the highest quality products and services.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.